GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apontis Pharma AG (XTER:APPH) » Definitions » Net-Net Working Capital

Apontis Pharma AG (XTER:APPH) Net-Net Working Capital : €0.59 (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Apontis Pharma AG Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Apontis Pharma AG's Net-Net Working Capital for the quarter that ended in Dec. 2024 was €0.59.

The industry rank for Apontis Pharma AG's Net-Net Working Capital or its related term are showing as below:

XTER:APPH's Price-to-Net-Net-Working-Capital is ranked worse than
77.17% of 403 companies
in the Drug Manufacturers industry
Industry Median: 8.09 vs XTER:APPH: 19.75

Apontis Pharma AG Net-Net Working Capital Historical Data

The historical data trend for Apontis Pharma AG's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apontis Pharma AG Net-Net Working Capital Chart

Apontis Pharma AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net-Net Working Capital
Get a 7-Day Free Trial -1.86 2.46 2.52 0.37 0.59

Apontis Pharma AG Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.52 1.73 0.37 0.41 0.59

Competitive Comparison of Apontis Pharma AG's Net-Net Working Capital

For the Drug Manufacturers - Specialty & Generic subindustry, Apontis Pharma AG's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apontis Pharma AG's Price-to-Net-Net-Working-Capital Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Apontis Pharma AG's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Apontis Pharma AG's Price-to-Net-Net-Working-Capital falls into.


;
;

Apontis Pharma AG Net-Net Working Capital Calculation

Apontis Pharma AG's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2024 is calculated as

Net-Net Working Capital(A: Dec. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(15.455+0.75 * 0.067+0.5 * 5.468-13.357
-0-0)/8.330
=0.59

Apontis Pharma AG's Net-Net Working Capital (NNWC) per share for the quarter that ended in Dec. 2024 is calculated as

Net-Net Working Capital(Q: Dec. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(15.455+0.75 * 0.067+0.5 * 5.468-13.357
-0-0)/8.330
=0.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Apontis Pharma AG  (XTER:APPH) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Apontis Pharma AG Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Apontis Pharma AG's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Apontis Pharma AG Business Description

Traded in Other Exchanges
N/A
Address
Rolf-Schwarz-Schutte-Platz 1, Monheim, BY, DEU, 40789
Apontis Pharma AG is a pharmaceutical company specializing in single pills in Germany. single pills combine two to three generic active ingredients in a single dosage form. The company develops, promotes, and sells a broad portfolio of single pills and other pharmaceutical products, with a special focus on cardiovascular diseases. The company markets drugs in the disease areas of respiratory diseases and diabetes as part of co-marketing/co-promotion.
Executives
Bruno Wohlschlegel Board of Directors
Thomas Milz Board of Directors
Thomas Zimmermann Chief Financial Officer
Karlheinz Gast Board of Directors

Apontis Pharma AG Headlines

No Headlines